Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
Interested parties may access the live webcast for this presentation byvisiting the "Events" section of the homepage of the Company's website atwww.labopharm.com. Please connect at least 15 minutes prior to thepresentation to ensure adequate time for any software download that may berequired to join the webcast. An audio archive of the presentation will beavailable for 30 days.
About the CIBC World Markets 18th Annual Healthcare Conference
The CIBC World Markets 18th Annual Healthcare Conference will feature acore group of public and private companies who are pioneering thepharmaceutical, biotechnology, medical device, healthcare facility, healthcaretechnology and distribution, provider and service industries. Presentationswill address topical issues such as Medicare and Medicaid reform, generic drugregulation, development of new blockbuster pharmaceutical and biotechnologyproducts, product safety and patent issues, cross-border reimportation, Foodand Drug Administration policy, managed care, and a comprehensive look at thecurrent M&A environment.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existingsmall molecule drugs using its proprietary controlled-release technologies.The Company's lead product, a unique once-daily formulation of tramadol, isbeing commercially launched in key markets globally. The Company has a robustpipeline of follow-on products in both pre-clinical and clinical development.Labopharm's vision is to become a fully integrated, international, specialtypharmaceutical company with the capability to internally develop andcommercialize its own products. For more information, please visitwww.labopharm.com.
This press release contains forward-looking statements, which reflect theCompany's current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual events could differmaterially from those projected herein and depend on a number of factors,including the uncertainties related to the regulatory process and thecommercialization of the Company's products thereafter, if they are approved.Investors should consult the Company's ongoing quarterly filings and annualreports for additional information on risks and uncertainties relating tothese forward-looking statements. The reader is cautioned not to rely on theseforward-looking statements. The Company disclaims any obligation to updatethese forward-looking statements.
SOURCE Labopharm Inc.
You May Also Like